Company Profile
Monte Rosa Therapeutics Stock Price, News & Analysis
- Ticker:
- GLUE
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
15.71 USD (+0.64%)
Close
Last updated: August 6, 2026
1.5B USD
Market cap
Why the stock is moving
The latest company update was “Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates”. GLUE changed 0.64% and closed at $15.71 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.
Company overview
Molecular Glue Degraders
Monte Rosa Therapeutics develops small-molecule molecular glues that redirect cellular machinery to degrade disease-causing proteins. The platform is intended to address targets that are difficult to inhibit conventionally.
MRT-8102
MRT-8102 is a NEK7-directed molecular glue degrader being developed for inflammatory and cardiometabolic diseases. Clinical work includes cardiovascular-risk, gout and hidradenitis-suppurativa populations.
MRT-2359 and Oncology Pipeline
MRT-2359 targets GSPT1 and is being evaluated with androgen-receptor inhibitors in metastatic castration-resistant prostate cancer.
Cyclin E1 Program
Monte Rosa is preparing a selective cyclin E1-directed molecular glue degrader for clinical development in tumors driven by cyclin E dysregulation.
Future catalysts
Initiation of a Phase 2 cardiovascular-risk study of MRT-8102 in the second half of 2026.
Expanded GFORCE-1 data for MRT-8102 in the second half of 2026.
Initiation of a Phase 2 study of MRT-2359 plus apalutamide in the third quarter of 2026.
IND submission for the cyclin E1 degrader in the second half of 2026.
Initiation of MRT-8102 Phase 2 studies in gout in the fourth quarter of 2026 or first quarter of 2027 and in hidradenitis suppurativa in the first half of 2027.
Recent news
- 01
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Source: Monte Rosa Therapeutics
- 02
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Source: Monte Rosa Therapeutics
- 03
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Source: Monte Rosa Therapeutics
- 04
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Source: Monte Rosa Therapeutics
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics (GLUE) most recently closed at 15.71 USD, a +0.64% move versus the previous session.
What is the market cap of Monte Rosa Therapeutics (GLUE)?
Monte Rosa Therapeutics currently has a market capitalization of 1.5B USD on BioPharmSignal.
What does Monte Rosa Therapeutics do?
Molecular Glue Degraders Monte Rosa Therapeutics develops small-molecule molecular glues that redirect cellular machinery to degrade disease-causing proteins. The platform is intended to address targets that are difficult to inhibit conventionally. MRT-8102 MRT-8102 is a NEK7-directed molecular glue degrader being developed for inflammatory and...
On which exchange is GLUE stock listed?
Monte Rosa Therapeutics (GLUE) is associated with NASDAQ, United States, Biopharma.
What is MRT-8102?
Initiation of a Phase 2 cardiovascular-risk study of MRT-8102 in the second half of 2026.
Which conditions is Monte Rosa Therapeutics targeting with MRT-8102?
Monte Rosa Therapeutics is associated with oncology, cancer therapeutics, cardiovascular disease based on its company overview and current catalyst commentary.
How does Monte Rosa Therapeutics describe recent progress with MRT-8102?
Initiation of a Phase 2 cardiovascular-risk study of MRT-8102 in the second half of 2026.
What is MRT-2359?
MRT-2359 and Oncology Pipeline MRT-2359 targets GSPT1 and is being evaluated with androgen-receptor inhibitors in metastatic castration-resistant prostate cancer.